Novartis: Burkitt Lymphoma trials
The registry lists 12 Burkitt Lymphoma studies with Novartis as lead sponsor. 2 are open to participants now and 6 have results posted.
Phase 1 3Phase 2 8Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Long-term Follow up Local Registry Study of Kymriah in South KoreaRecruitingNCT06785818
- Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 3
- Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04225676Phase 2Results posted
- Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedNCT03610724Phase 2Results posted
- Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02435849Phase 2Results posted
- Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02228096Phase 2Results posted
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)TerminatedNCT01685021Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingNCT05397496Phase 1
- Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALLWithdrawnNCT04156659Phase 2
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive, not recruitingNCT03876769Phase 2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1